Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APOHEALTH Cystitis Relief
- Development stage
- Unknown
- Lead developer
- Arrotex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
APOHEALTH Cystitis Relief is an over-the-counter urinary alkaliniser formulated as effervescent granules. It contains a combination of sodium bicarbonate, tartaric acid, citric acid, and sodium citrate. The drug is indicated for the symptomatic relief of the burning pain and discomfort associated with cystitis (urinary tract infections) in adults and children aged 12 years and older. By raising the pH of the urine, it reduces acidity, thereby alleviating the irritation of the inflamed bladder and urethral mucosa during urination. It is marketed as a generic alternative to Ural.
- Brand names
- APOHEALTH Cystitis Relief
- Other names
- ApoHealth Cystitis Reliefcitric acid + sodium bicarbonate + sodium citrate + tartaric acid
Beyond the preview
Go deeper on APOHEALTH Cystitis Relief.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APOHEALTH Cystitis Relief.